Pulike Biological Engineering (603566) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pulike Biological Engineering (603566) has a cash flow conversion efficiency ratio of 0.034x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥87.38 Million ≈ $12.79 Million USD) by net assets (CN¥2.58 Billion ≈ $377.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pulike Biological Engineering - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Pulike Biological Engineering's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Pulike Biological Engineering carry for a breakdown of total debt and financial obligations.
Pulike Biological Engineering Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pulike Biological Engineering ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Solowin Holdings
NASDAQ:AXG
|
-0.002x |
|
Everbright Jiabao Co Ltd
SHG:600622
|
0.033x |
|
CCCG Real Estate Corp Ltd
SHE:000736
|
-0.306x |
|
Weihai Huadong Automation Co Ltd
SHE:002248
|
0.044x |
|
Stendörren Fastigheter AB (publ)
ST:STEF-B
|
0.020x |
|
Zhejiang Tengen Electrics Co Ltd
SHG:605066
|
N/A |
|
FBD Holdings PLC
IR:EG7
|
0.016x |
|
RattanIndia Power Limited
NSE:RTNPOWER
|
0.082x |
Annual Cash Flow Conversion Efficiency for Pulike Biological Engineering (2010–2024)
The table below shows the annual cash flow conversion efficiency of Pulike Biological Engineering from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Pulike Biological Engineering.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.63 Billion ≈ $384.28 Million |
CN¥268.79 Million ≈ $39.33 Million |
0.102x | -1.41% |
| 2023-12-31 | CN¥2.72 Billion ≈ $398.59 Million |
CN¥282.78 Million ≈ $41.38 Million |
0.104x | +27.22% |
| 2022-12-31 | CN¥2.80 Billion ≈ $409.51 Million |
CN¥228.36 Million ≈ $33.42 Million |
0.082x | -30.87% |
| 2021-12-31 | CN¥1.80 Billion ≈ $263.46 Million |
CN¥212.53 Million ≈ $31.10 Million |
0.118x | -22.92% |
| 2020-12-31 | CN¥1.71 Billion ≈ $250.17 Million |
CN¥261.83 Million ≈ $38.31 Million |
0.153x | +81.24% |
| 2019-12-31 | CN¥1.66 Billion ≈ $242.62 Million |
CN¥140.10 Million ≈ $20.50 Million |
0.084x | +9.45% |
| 2018-12-31 | CN¥1.64 Billion ≈ $239.34 Million |
CN¥126.27 Million ≈ $18.48 Million |
0.077x | -14.02% |
| 2017-12-31 | CN¥1.57 Billion ≈ $229.57 Million |
CN¥140.86 Million ≈ $20.61 Million |
0.090x | -47.45% |
| 2016-12-31 | CN¥1.48 Billion ≈ $216.71 Million |
CN¥253.03 Million ≈ $37.03 Million |
0.171x | +22.12% |
| 2015-12-31 | CN¥1.34 Billion ≈ $195.68 Million |
CN¥187.09 Million ≈ $27.38 Million |
0.140x | -36.75% |
| 2014-12-31 | CN¥683.59 Million ≈ $100.03 Million |
CN¥151.21 Million ≈ $22.13 Million |
0.221x | -26.36% |
| 2013-12-31 | CN¥603.33 Million ≈ $88.29 Million |
CN¥181.21 Million ≈ $26.52 Million |
0.300x | -10.59% |
| 2012-12-31 | CN¥440.47 Million ≈ $64.45 Million |
CN¥147.96 Million ≈ $21.65 Million |
0.336x | -31.46% |
| 2011-12-31 | CN¥311.26 Million ≈ $45.55 Million |
CN¥152.54 Million ≈ $22.32 Million |
0.490x | +35.24% |
| 2010-12-31 | CN¥195.88 Million ≈ $28.66 Million |
CN¥70.98 Million ≈ $10.39 Million |
0.362x | -- |
About Pulike Biological Engineering
Pulike Biological Engineering, Inc. engages in the research, development, production, and sale of veterinary biological products, chemical drugs, and traditional Chinese veterinary drugs. The company offers vaccines, antibodies, and medicines for swine and poultry, as well as disinfectants. Pulike Biological Engineering, Inc. was founded in 1995 and is headquartered in Luoyang, China.